News
PMN
0.7690
-2.78%
-0.0220
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
Barchart · 3d ago
Weekly Report: what happened at PMN last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at PMN last week (0224-0228)?
Weekly Report · 03/03 11:47
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial
TipRanks · 02/25 12:33
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
TipRanks · 02/25 12:32
PROMIS NEUROSCIENCES INC - PRECISE-AD STUDY TO ENROLL APPROXIMATELY 100 SUBJECTS ACROSS 22 SITES
Reuters · 02/25 12:00
PROMIS NEUROSCIENCES DOSES FIRST PATIENTS IN PHASE 1B PRECISE-AD TRIAL OF PMN310 FOR ALZHEIMER’S DISEASE
Reuters · 02/25 12:00
Weekly Report: what happened at PMN last week (0217-0221)?
Weekly Report · 02/24 11:47
ProMIS Neurosciences Separates With Operating Chief, Won't Backfill Role
Dow Jones · 02/19 23:42
ProMIS Neurosciences dismisses COO position
Seeking Alpha · 02/19 22:53
ProMIS Neurosciences Announces COO Position Termination
TipRanks · 02/19 22:19
ProMIS Neurosciences seperates from COO Malenfant, terminates COO position
TipRanks · 02/19 22:10
Weekly Report: what happened at PMN last week (0210-0214)?
Weekly Report · 02/17 11:44
ProMIS Neurosciences Executive Makes Bold Stock Purchase
TipRanks · 02/13 02:05
Weekly Report: what happened at PMN last week (0203-0207)?
Weekly Report · 02/10 11:37
Weekly Report: what happened at PMN last week (0127-0131)?
Weekly Report · 02/03 11:42
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Barchart · 01/29 06:30
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus
TipRanks · 01/27 12:58
Weekly Report: what happened at PMN last week (0120-0124)?
Weekly Report · 01/27 11:46
More
Webull provides a variety of real-time PMN stock news. You can receive the latest news about Promis Neuroscie through multiple platforms. This information may help you make smarter investment decisions.
About PMN
More
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.